Monofosfato de adenosina cíclicen polvo

¿Qué es el campo cíclicde monofosfato de adenosina?

El monofosfato cíclicde adenosina (El campamento), también conocido como monofosfato cíclicde adenosina, es un inactivador de la proteína quinasa. También es un segundo mensajero implicado en la regulación de las funciones celulares y es una sustancia encontrada en el propio cuerpo humano. La ciclofosadenosina juega un papel en la regulación hormonal de las funciones fisiológicas y el metabolismo de sustancias dentro de la célula, y controla los procesos metabólicos dentro de la célula a través de proteínas quinasas para lograr la regulación de la célula por señales biológicas.

Earl Wilbur Sutherland, el descubrimiento del campo cíclicmonofosfato de adenosina y la introducción del segundo mensajero tomó a mankind's los misterios de la vida un paso gigantesco hacia adelante y sentó las bases para mucha investigación futura. Sutherland fue galardonado con el premio Nobel de fisiología/medicina en 1971.

El profesor Kandel de la universidad de Columbia en los Estados Unidos concluyó a través de la investigación que el campo cíclicmonofosfato de adenosina Tiene un papel muy importante en la reparación de las células cerebrales, la activación de las células cerebrales, y la regulación de la función de las células cerebrales. Convierte la memoria a corto plazo en memoria a largo plazo y alivia la fatiga de las células cerebrales y retrasel envejecimiento de las células cerebrales. Por esto, Kandel fue galardonado con el premio Nobel de medicina en 2000.

La tecnología de primavera verde suministra campos de monofosfato de adenosina cíclica en polvo, que es un monofosfato de adenosina cíclica de alta pureza (cAMP) con El 99% de pureza obtenida por la tecnología de enriquecimiento de extracción hipertérmica en frío.

Especificaciones: 

Normativa:

Se ajusta a la normativa de la UE.

Benefits:

Inhibition of Vascular Remodeling

The cyclic adenosine monophosphate (cAMP) pathway inhibits vascular remodeling by regulating downstream effector molecules to promote endothelial repair, inhibit endothelial proliferation, and inhibit platelet aggregation, etc. The main targets of cAMP are cAMP-dependent protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac). The two main targets of cAMP are cAMP-dependent protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac).

Protection of Vascular Endothelial Cells

Increased intracellular Cyclic Adenosine Monophosphate cAMP levels promote the expression of anti-inflammatory factors such as IL-10 and decrease the levels of pro-inflammatory factors such as IL-12. cAMP levels inhibit thrombin-induced calcium in-flow, thereby reducing permeability. Cyclic Adenosine Monophosphate cAMP also exerts endothelial protection by inhibiting the production of reactive oxygen species (ROS) in vascular endothelial cells and by increasing NO levels. cAMP also exerts endothelial protection by inhibiting the generation of reactive oxygen species (ROS) in vascular endothelial cells and elevating NO levels. The cAMP-PKA pathway also enhances DDAH promoter activity, protein expression, and enzyme activity. Promoting the inactivation of ADMA increases NO levels and promotes endothelial cell survival and proliferation. Inhibits ADMA-induced endothelial cell apoptosis.

Thus, in terms of the cyclophosphoadenosine pathway, elevated concentrations of cyclophosphoadenosine are effective in protecting vascular endothelial cells. Reduces thrombosis and lowers blood viscosity. Inhibit various inflammatory factors and reduce the permeability of vascular endothelial cells. At the same time, it promotes the survival of endothelial cells to follow the proliferation and inhibits their apoptosis, gives cellular energy, and dilates blood vessels. In clinical practice, cyclophosphoadenosine has a good effect on cardiovascular and cerebrovascular diseases, related inflammatory diseases, and diseases that require energy supplementation.

Improves Myocardial Contractility

Studies have shown that activation of the renin-angiotensin-aldosterone system is involved in a variety of vascular remodeling processes. Angiotensin II has been shown to induce migration, proliferation, and apoptosis in VSMCs Elevating intracellular Cyclic Adenosine Monophosphate cAMP water may regulate cytoskeletal remodelling by inhibiting RhoA activity via cAMP-Eapc-Rap1. This in turn inhibited the migration and endothelial proliferation of VSMCs. Elevated intracellular cAMP levels also inhibit vascular fibrosis. cAMP increases intracellular calcium ion levels through the activation of cyclic nucleotide cation-gated channels. This in turn promotes lysosomal degradation of type I collagen and reduces the intracellular secretion to extracellular type I collagen content in VSMCs.

From the Cyclic Adenosine Monophosphate cAMP pathway, elevated cyclophosphoadenosine concentrations inhibit migration and intimal hyperplasia of vascular smooth muscles (VSMCs). It promotes lysosomal degradation of type I collagen and reduces the intracellular and secretion to extracellular type I collagen in VSMCs. To achieve the effect of protecting vascular smooth muscle. Moreover, cAMP increases the intracellular calcium ion level by activating cyclic nucleotide cation-gated channels, which leads to Ca2+ inward flow and enhances phosphorylation. It promotes excitation-contraction coupling, improves myocardial contractility and plays a positive inotropic effect.

At the same time, it can promote sarcoplasmic reticulum calcium pumping action, pumping back Ca2+ , so that the free Ca2+ in the sarcoplasmic reticulum is reduced. Accelerate myocardial diastole, coronary artery dilation. In the clinic, cyclophosphorus adenosine has a good therapeutic effect in cardiovascular and cerebrovascular diseases, respiratory diseases and so on.

Inhibition of Pathological Pain

Feng et al. found that drugs that directly enhanced intracellular powered Cyclic Adenosine Monophosphate cAMP  activity (8-Br-cAMP and cholera toxin) both down-regulated the mRNA transcription of IL-12 after endotoxin-stimulated endocytosis in mouse peritoneal macrophages cultured in vitro and inhibited the secretion of IL-12 and that this effect did not depend on PKA activation, which may be related to the inhibition of mitogen-activated protein kinase (MAPK) p38 activation. activated protein kinase (MAPK) p38 and the effect was not dependent on PKA activation.

Aronoff et al. further observed the effects of PKA and selective agonists of the Epac pathway of Cyclic Adenosine Monophosphate cAMP on the inflammatory activity of endotoxin-stimulated alveolar macrophages cultured in vitro and found that activation of Epac alone dose-dependently inhibited phagocytosis, activation of PKA alone reduced the release of leukotriene B4 and TNF-α, and activation of either Epac or PKA inhibited the bactericidal activity of the cells as well as the secretion of hydrogen peroxide.

The above studies used a variety of drugs to regulate the cAMP pathway and selected different inflammatory cells, but the results suggest that the activation of the Cyclic Adenosine Monophosphate cAMP pathway in inflammatory cells may regulate the activity of transcription factors NF-κB and CREB through the PKA and/or Epac pathways. This reduces the release of pro-inflammatory factors such as TNF-α and IL-12 and inhibits inflammatory cell activation. In conclusion, an increase in cyclophosphoadenosine concentration can inhibit mitogen-stimulated inflammatory cell, astrocyte, and microglia activation, and reduce the production of various pro-inflammatory and analgesic factors, thus inhibiting pathological pain.

Inhibition of Cytokine Secretion by Microglia

Activated Cyclic Adenosine Monophosphate cAMP pathway inhibited IL-1β release from activated microglia, and PKA and Epac pathways exerted different effects on endotoxin-stimulated inflammatory cytokine release from microglia. Both were involved in the inhibition of TNF-α release, but only the PKA pathway inhibited the release of IL-1β and promoted the secretion of the anti-inflammatory cytokine IL-10.

Improving Cognitive Performance

The cAMP-PKA-CREB signaling pathway plays an important role in learning and memory. Increased calcium in postsynaptic neurons activates adenylate cyclase, causing cAMP expression and PKA activation. cAMP leads to the transport of MAPK to the nucleus, which then activates CREB, causing the expression of downstream target genes and the synthesis of new proteins. Finally, the new synthetic material can lead to the growth of primary synapses and the formation of new synapses, which are the basis for synaptic plasticity and learning memory. Activation of the cAMP-PKA-CREB signaling pathway promotes the expression of BDNF, pCREB, and CREB in the hippocampus, thereby ameliorating cognitive dysfunction in traumatized rats.

Applications:

For Health Products:

Kandel has been honoured with the research clarifying that Adenosine Cyclic Phosphate is able to prevent the aging of brain cells and plays a decisive role in the activation function of aging brain cells. Adenosine Cyclic Phosphate has the function of promoting brain cell metabolism, repairing aging and fatigued brain cells, slowing down the aging of brain cells, keeping the metabolism of brain cells in a vigorous state, achieving vigorous self-renewal of organisms, and at the same time enhancing memory. Powdered Adenosine Cyclic Phosphate has been used as an additive in health products.